AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10972634 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan (100 mg)
Number of subjects: 253
Study 8958893 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppb nitrogen dioxide (NO2) + 200 ppb sulphur dioxide (SO2)
Number of subjects: 13
Study 8958893 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 13
Study 1347965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 29
Study 1347965 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 29
Study 3513530 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 546
Study 3513530 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 546
Study 3513530 — intervention group
Group type: COMPARATOR
Intervention: Clonidine withdrawal
Number of subjects: 546
Study 3513530 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine withdrawal
Number of subjects: 546
Study 28540570 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg magnesium oxide supplements daily for 12 weeks
Number of subjects: 70
Study 27207543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg once daily for 10 days)
Number of subjects: 61
Study 27207543 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin [9-39] (high-dose intravenous infusion)
Number of subjects: 61
Study 27207543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24976347 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Triple P training
Number of subjects: 0
Study 24976347 — intervention group
Group type: COMPARATOR
Intervention: Control residents
Number of subjects: 0
Study 23446891 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-palmitic acid and high-oleic acid diet (HOA)
Number of subjects: 32
Study 23446891 — intervention group
Group type: COMPARATOR
Intervention: High-palmitic acid diet (HPA)
Number of subjects: 32
Study 20497977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal growth restriction (FGR)
Number of subjects: 200
Study 20497977 — intervention group
Group type: COMPARATOR
Intervention: Normally grown fetuses (Control)
Number of subjects: 200
Study 18468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg i.v. (Group M, n = 101)
Number of subjects: 210
Study 18468014 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg i.v. with fentanyl 25 microg (Group MF, n = 100)
Number of subjects: 210
Study 15915034 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg clonidine plus 500 microg neostigmine
Number of subjects: 0
Study 15915034 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg clonidine plus 750 microg neostigmine
Number of subjects: 0
Study 15915034 — intervention group
Group type: COMPARATOR
Intervention: 150 microg clonidine
Number of subjects: 0
Study 15915034 — intervention group
Group type: COMPARATOR
Intervention: 750 microg neostigmine
Number of subjects: 0
Study 15915034 — intervention group
Group type: COMPARATOR
Intervention: 75 microg clonidine plus 250 microg neostigmine
Number of subjects: 0
Study 15915034 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 0
Study 12832366 — intervention group
Group type: EXPERIMENTAL
Intervention: EFORT
Number of subjects: 110
Study 12832366 — intervention group
Group type: COMPARATOR
Intervention: CCT
Number of subjects: 110
Study 11056328 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 8897562 — intervention group
Group type: COMPARATOR
Intervention: Prednisone, 40 mg/m2 on alternate days for 12 months (control group)
Number of subjects: 60
Study 8897562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 40 mg/m2 on alternate days for 12 months plus a 90‐day course of daily cyclophosphamide, 2.5 mg/kg in a single morning dose (experimental group)
Number of subjects: 60
Study 8897562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and experimental)
Number of subjects: 60
Study 1510519 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated closed-loop titration system
Number of subjects: 1089
Study 1510519 — intervention group
Group type: COMPARATOR
Intervention: Manual nitroprusside titration
Number of subjects: 1089
Study 6356343 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole gel
Number of subjects: 51
Study 6356343 — intervention group
Group type: COMPARATOR
Intervention: Nystatin suspension
Number of subjects: 51
Study 31415797 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy x 5
Number of subjects: 203
Study 31415797 — intervention group
Group type: COMPARATOR
Intervention: 3 Gy x 10
Number of subjects: 203
Study 30407098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PEMBRO)
Number of subjects: 400
Study 30407098 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab + Nivolumab (IPI+NIVO)
Number of subjects: 400
Study 26937921 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure oxygen (FiO2=100%)
Number of subjects: 17
Study 26937921 — intervention group
Group type: COMPARATOR
Intervention: Medical air (FiO2=21%)
Number of subjects: 17
Study 24798395 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐h self‐management programme
Number of subjects: 207
Study 24798395 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study 24798395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 207
Study 22144721 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 56
Study 22144721 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 56
Study 20200550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 1527
Study 20200550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1527
Study 20200550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study 17659823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuna fish oil
Number of subjects: 83
Study 17659823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 16336487 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of a new uro-selective alpha-blocker
Number of subjects: 536
Study 16336487 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of a new uro-selective alpha-blocker
Number of subjects: 536
Study 16336487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 16336487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of a new uro-selective alpha-blocker
Number of subjects: 536
Study 12386911 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOFF administered orally
Number of subjects: 185
Study 12386911 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOFF administered in written format
Number of subjects: 185
Study 12386911 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOFF administered verbally first
Number of subjects: 185
Study 10363956 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical task (judging whether a dot was above or below a horizontal line)
Number of subjects: 0
Study 10363956 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinate task (judging the distance between the dot and the bar)
Number of subjects: 0
Study 8576893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy including a diuretic
Number of subjects: 102
Study 8576893 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy without a diuretic
Number of subjects: 102
Study 8576893 — intervention group
Group type: COMPARATOR
Intervention: Single drug treatment (hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem-SR, prazosin)
Number of subjects: 102
Study 8576893 — intervention group
Group type: COMPARATOR
Intervention: Combinations containing prazosin
Number of subjects: 102
Study 2196311 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) 40 KE X 1/W
Number of subjects: 88
Study 2196311 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) 20 KE X 3/W
Number of subjects: 88
Study 2196311 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) 5 KE X 3/W
Number of subjects: 88
Study 2196311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 377202 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 units of dl‐alpha tocopherol
Number of subjects: 28
Study 377202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29866635 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute straw phonation exercise
Number of subjects: 24
Study 29866635 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute straw phonation exercise
Number of subjects: 24
Study 29866635 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 24
Study 28594709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (AOX) supplementation
Number of subjects: 93
Study 28594709 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 93
Study 25687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (CBZ)
Number of subjects: 25
Study 25687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (CLN)
Number of subjects: 25
Study 25687539 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (TLT)
Number of subjects: 25
Study 23400548 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2.4 gm/day
Number of subjects: 49
Study 23400548 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 4.8 gm/day
Number of subjects: 49
Study 23400548 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2.4 gm/day and 4.8 gm/day combined
Number of subjects: 49
Study 23400548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 21327344 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects with strong perceptual features at decision points
Number of subjects: 0
Study 21327344 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects with strong perceptual features at non-decision points
Number of subjects: 0
Study 21327344 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual features
Number of subjects: 0
Study 21327344 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial features
Number of subjects: 0
Study 21327344 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation of perceptual and spatial features
Number of subjects: 0
Study 19801363 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (exenatide, liraglutide)
Number of subjects: 27
Study 19801363 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (sitagliptin, alogliptin, saxagliptin)
Number of subjects: 27
Study 19801363 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (diet and exercise)
Number of subjects: 27
Study 19801363 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (oral antihyperglycemic regimens)
Number of subjects: 27
Study 19281053 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 0
Study 19281053 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 19281053 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 15780108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 179
Study 15780108 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 179
Study 15780108 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcification score
Number of subjects: 179
Study 15780108 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes, C-reactive protein (CRP), diastolic blood pressure, gender, smoking, hypertension
Number of subjects: 179
Study 12032025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron continuous infusion (1 mg. mL(‐1). h(‐1))
Number of subjects: 59
Study 12032025 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control Group T)
Number of subjects: 59
Study 9442775 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (5 fractions of 200 cGy 6 MV external beam photons)
Number of subjects: 91
Study 9442775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiation therapy)
Number of subjects: 91
Study 7633300 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment at Clinic 2 (long-term maintenance)
Number of subjects: 202
Study 7633300 — intervention group
Group type: COMPARATOR
Intervention: Time-limited treatment aimed at abstinence at Clinic 1
Number of subjects: 202
Study 7633300 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone dose of 80 mg/day
Number of subjects: 202
Study 7633300 — intervention group
Group type: EXPERIMENTAL
Intervention: Average doses prescribed in Clinic 1 (lower doses)
Number of subjects: 202
Study 2520344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (approximately 28 mg delivered into the mouth)
Number of subjects: 16
Study 2520344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (the diluent)
Number of subjects: 16
Study 238278 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimepranol (15 mg daily for 16 weeks)
Number of subjects: 0
Study 238278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during control period)
Number of subjects: 0
Study 30861617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 500
Study 30861617 — intervention group
Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 500
Study 29681434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg b.i.d. plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Number of subjects: 76
Study 29681434 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Number of subjects: 76
Study 28886745 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (optimal dose)
Number of subjects: 0
Study 28886745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26259064 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) drugs
Number of subjects: 286
Study 26259064 — intervention group
Group type: COMPARATOR
Intervention: Non-TCM hospitals
Number of subjects: 286
Study 23560491 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise (Group 2) - training load of 40% of one repetition maximum (1RM) with anklets, three series of 15 repetitions
Number of subjects: 32
Study 23560491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Group 3) - pedaled seated in the dialysis seat for 20 min on an ergometric bicycle, intensity regulated by perceived effort scale
Number of subjects: 32
Study 23560491 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1) - no physical training
Number of subjects: 32
Study 21139088 — intervention group
Group type: EXPERIMENTAL
Intervention: ASMA (Asthma Self‐Management for Adolescents)
Number of subjects: 345
Study 21139088 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 345
Study 18286692 — intervention group
Group type: EXPERIMENTAL
Intervention: New reconstructive method using fast-absorbable suture material (irradiated polyglactin 910) and a temporary stent tube
Number of subjects: 63
Study 18286692 — intervention group
Group type: COMPARATOR
Intervention: Conventional duct-to-mucosa anastomosis
Number of subjects: 63
Study 16773409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril and prednisone for 12 weeks
Number of subjects: 45
Study 16773409 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone for 12 weeks
Number of subjects: 45
Study 14690574 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeloda and radiotherapy (Group B)
Number of subjects: 60
Study 14690574 — intervention group
Group type: COMPARATOR
Intervention: Operation alone (Group A)
Number of subjects: 60
Study 10722990 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to walking trails
Number of subjects: 1269
Study 10722990 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of walking trails
Number of subjects: 1269
Study 10722990 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics of trail users
Number of subjects: 1269
Study 10722990 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level and walking increase
Number of subjects: 1269
Study 8704804 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 1 mg/kg injected transvaginally or 1.5 mg/kg IM if necessary (group 1)
Number of subjects: 89
Study 8704804 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingotomy (group 2)
Number of subjects: 89
Study 8704804 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 89
Study 8704804 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingotomy
Number of subjects: 89
Study 8704804 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and Laparoscopic salpingotomy
Number of subjects: 89
Study 1495823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 1495823 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 6666698 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily calorie referencing with no further calorie goals
Number of subjects: 0
Study 6666698 — intervention group
Group type: COMPARATOR
Intervention: Immediate calorie referencing with subgoals for meals and snacks
Number of subjects: 0
Study 31148436 — intervention group
Group type: EXPERIMENTAL
Intervention: 2017 AHA/ACC guideline criteria (BP ≥ 130/80 mmHg)
Number of subjects: 3420
Study 30767504 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask
Number of subjects: 6629
Study 30767504 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 6629
Study 27035501 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 25
Study 27035501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 26248454 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma eardrum perforation homochronous with palatoplasty
Number of subjects: 56
Study 26248454 — intervention group
Group type: COMPARATOR
Intervention: Palatoplasty alone (Control)
Number of subjects: 56
Study 22361603 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 51
Study 22361603 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 51
Study 20622335 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Polygonum multiflorum extract
Number of subjects: 209
Study 20622335 — intervention group
Group type: COMPARATOR
Intervention: Polygonum multiflorum extract (Chinese herb control)
Number of subjects: 209
Study 20622335 — intervention group
Group type: COMPARATOR
Intervention: Naofukang (western medicine control)
Number of subjects: 209
Study 18630111 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling-Root Planing (SRP)
Number of subjects: 60
Study 18630111 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Nd: YAG laser irradiation
Number of subjects: 60
Study 18630111 — intervention group
Group type: COMPARATOR
Intervention: Nd: YAG laser irradiation alone
Number of subjects: 60
Study 15789103 — intervention group
Group type: EXPERIMENTAL
Intervention: Galloy restorations
Number of subjects: 14
Study 15789103 — intervention group
Group type: COMPARATOR
Intervention: Dispersalloy restorations
Number of subjects: 14
Study 12354084 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser radiation at 60 mJ
Number of subjects: 85
Study 12354084 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser radiation at 100 mJ
Number of subjects: 85
Study 12354084 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser radiation at 180 mJ
Number of subjects: 85
Study 12354084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical treatment using curettes
Number of subjects: 85
Study 12354084 — intervention group
Group type: COMPARATOR
Intervention: Untreated control samples
Number of subjects: 85
Study 10407818 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (0.5 mg/kg/h continuous infusion)
Number of subjects: 34
Study 10407818 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (loading dose 5 mg/kg, 3 mg/kg bid)
Number of subjects: 34
Study 10407818 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 34
Study 10407818 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 34
Study 7592232 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (self-efficacy enhancement)
Number of subjects: 25
Study 7592232 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study 2075080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 68
Study 2075080 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 68
Study 2075080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both agents (Cefuroxime + Metronidazole)
Number of subjects: 68
Study 2075080 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 68
Study 7013057 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (home-training and group-training led by a physiotherapist) for 4 to 8 years
Number of subjects: 46
Study 7013057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 46
Study 31145109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight exercises (Cook hip lift)
Number of subjects: 20
Study 31145109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight exercises
Number of subjects: 20
Study 29284737 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized regular coaching on physical activity and exercise every month for 18 consecutive months
Number of subjects: 380
Study 29284737 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized regular coaching on physical activity and exercise
Number of subjects: 380